Safety of vaccines...

-please provide scientific evidence on ANY study which can confirm the long-term safety and effectiveness of vaccines?

Apparently you have no familiarity with PubMed.  When "vaccine safety" is entered there, you will retrieve 12000+ references!   Here's 20 related to just the flu vaccine:

Greene SK, Kulldorff M, Lewis EM et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am. J. Epidemiol. 171(2), 177–188(2010).

Lee GM, Greene SK, Weintraub ES et al.; Vaccine Safety Datalink Project. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am. J. Prev. Med. 41(2), 121–128(2011).

Vasil'eva RI, Merkur'eva LA, Iatsenko VG, Vasil'eva AM, Shvager MM. Characteristics of the clinical and immunologic safety of inactivated influenza vaccines in children undergoing multiple immunizations. Zh. Mikrobiol. Epidemiol. Immunobiol. 11, 65–69(1988).

Barry DW, Mayner RE, Hochstein HD et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am. J. Epidemiol. 104(1), 47–59(1976).

France EK, Glanz JM, Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch. Pediatr. Adolesc. Med. 158(11), 1031–1036(2004).

Glanz JM, Newcomer SR, Hambidge SJ et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch. Pediatr. Adolesc. Med. 165(8), 749–755(2011).

Hambidge SJ, Glanz JM, France EK et al.; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296(16), 1990–1997(2006). (Provides information on the safety of inactivated influenza vaccine in a large population of children 6–23 months of age.)

Kelso JM, Li JT, Nicklas RA et al.; Joint Task Force on Practice Parameters; Joint Task Forcce on Practice Parameters for Allergy & Immunology. Adverse reactions to vaccines. Ann. Allergy Asthma Immunol. 103(4 Suppl. 2), S1–S14(2009).

Wood RA, Berger M, Dreskin SC et al.; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 122(3), e771–e777(2008).

Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6–23 months of age. Vaccine 27(32), 4278–4283(2009).

Wood N, Sheppeard V, Cashman P et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr. Infect. Dis. J. 31(2), 199–202(2012).

Varricchio F, Iskander J, Destefano F et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 23(4), 287–294(2004).

Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23(2), 138–144(2004).

Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr. Infect. Dis. J. 27(5), 444–452(2008).

 King JC Jr, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177(5), 1394–1397(1998).

 Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21(11–12), 1224–1231(2003).

 Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116(3), e397–e407(2005).

Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110(4), 662–672(2002).

 Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. J. 21(1), 44–48(2002).

 Zangwill KM, Droge J, Mendelman P et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr. Infect. Dis. J. 20(8), 740–746(2001).